Observational studyObesity (Silver Spring, Md.)2025
Perceptions of anti-obesity medications among people with obesity and healthcare providers in the US: Findings from the OBSERVE Study.
Observational study in Obesity (Silver Spring, Md.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Sociodemographic and socioeconomic differences in the use of anti-obesity medications: a register study among 282,307 Finnish adults.International journal of obesity (2005) · 2026Article
- A Practical Perspective on Confronting the Obesity Epidemic: Public-Health Strategies.Nutrients · 2026Review
- The New Obesity Treatment Landscape: Challenges and Opportunities to Promote Shared Decision-Making in People With Obesity and Type 2 Diabetes.Diabetes care · 2026Review
- Attitudes Toward Injectable GLP-1 Drugs for Obesity Treatment: A Qualitative Interview Study With Healthcare Professionals.Obesity science & practice · 2026Article
- A treat-to-target approach for obesity management: A post hoc analysis of the SURMOUNT-5 trial.Diabetes, obesity & metabolism · 2026Observational
- The long-term effectiveness of the anti-obesity medication phentermine (LEAP) trial: Rationale, design, and baseline characteristics.Contemporary clinical trials · 2026Article
- Considering Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) for Weight Loss: Insights from a Pragmatic Mixed-Methods Study of Patient Beliefs and Barriers.Healthcare (Basel, Switzerland) · 2026Article
- Exploring the Role of Internalized Weight Bias as a Metric of Cumulative Social Disadvantage Among People With Obesity or Overweight: Insights From the OBSERVE Study.Obesity science & practice · 2025Article
- Perceptions of anti-obesity medications among people with obesity and healthcare providers in the US: Findings from the OBSERVE Study.Obesity (Silver Spring, Md.) · 2025Observational
- Barriers to glucagon-like peptide-1 agonists used for obesity management among the general population in Tabuk City, Saudi Arabia, and their relation to smoking cessation and antidepressants.Frontiers in pharmacology · 2025Article
- Obesity Medication Treatment Perspectives Among People with Overweight or Obesity.Patient preference and adherence · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectiveThe objective of this study was to understand the perceptions of and drivers/barriers to antiobesity medication (AOM) use among people with obesity (PwO) and health care providers (HCPs) in the United States.
methodsIn 2022, PwO and HCPs completed cross-sectional surveys that included questions on perceptions of obesity management and AOMs. Data were analyzed using descriptive statistics.
resultsSurvey participants (1007 PwO and 474 HCPs) emphasized the effectiveness of lifestyle change and the patient's responsibility to address obesity. PwO reported a willingness to take newly approved AOMs long term. HCPs believed that their patients would adhere to AOMs long term if they experienced success. Both PwO and HCPs perceived an increased effectiveness of a multimodal approach to combining AOMs with HCP-guided lifestyle intervention. Potential barriers to long-term use of AOMs for both groups included concerns regarding long-term side effects and outcomes, costs and insurance coverage, and perception of AOMs that do not align with treatment of a chronic disease.
conclusionsPwO and HCPs are interested in new AOM options, but educational gaps remain as a barrier to recommended multimodal chronic care. Ongoing education that includes the known effectiveness and safety data of newer AOMs and pending outcome trials could improve shared decision-making in obesity care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.